Identification and Characterization of New Chemical Entities Targeting Apurinic/Apyrimidinic Endonuclease 1 for the Prevention of Chemotherapy-Induced Peripheral Neuropathy

What is it about?

The data and studies presented in this manuscript describe the identification of potential new drugs that can prevent or reverse chemotherapy induced peripheral neuropathy, a major problem for a significant number of patients undergoing cancer treatments.

Featured Image

Why is it important?

One of the major concerns with a number of commonly used anticancer drugs is the development of chemotherapy-induced peripheral neuropathy (CIPN) which can limit patients from receiving truly therapeutic levels of these drugs. This can have a significant impact on quality of life both during and after therapy. Furthermore, unlike a number of other major side effects of chemotherapy [e.g. nephrotoxicity, bone marrow suppression, there are no effective treatments to prevent or reverse CIPN. Thus, there is a vital need to develop treatment strategies for CIPN based on the discovery of mechanisms mediating this neurotoxicity. There are no FDA approved drugs to treat CIPN. We have been studying the underlying mechanism of CIPN and have advanced some studies and potential new compounds that have promise to address this problem.

Perspectives